GLP-1 clinical trials in Georgia: 23 recruiting now

23 GLP-1 clinical trials are recruiting at 48 sites in 23 cities across Georgia. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Georgia

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   2 sites in Georgia

   • NSC Research, Inc., Johns Creek. 678-507-0838
   • Herman Clinical Research, Suwanee. 678-739-2765

2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   2 sites in Georgia

   • Atlanta Research Center for Rheumatology, Marietta. 7703723962
   • Satilla Rheumatology & Internal Medicine, Waycross. 9125480710

3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

   Who can join. Adults 18+, have psoriasis, BMI 27+.

   1 site in Georgia

   • Southeast Research Specialists, Douglasville. 678-702-3376

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   4 sites in Georgia

   • Southeast Clinical Research Center, Dalton. 706-913-1779
   • Teak Research Consults, Lawrenceville
   • Gastrointestinal Specialists of Georgia, Marietta. 404-786-3100
   • Rophe Adult and Pediatric Medicine/SKYCRNG, Union City. 470-317-3604

5. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

   A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

   Who can join. Children and teens 8 to 18, are overweight.

   4 sites in Georgia

   • Children's Healthcare Atlanta, Atlanta
   • Columbus Research Foundation, Columbus
   • Accel Research Sites-NeuroStudies, Decatur
   • Eastside Bariatric and Gen Surg, Snellville

6. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   4 sites in Georgia

   • Hope Clin Res & Wellness, Conyers
   • Center for Adv Res & Education, Gainesville
   • Endocrine Research Solutions, Inc, Roswell
   • North Georgia Clinical Research, Woodstock

7. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

   Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

   4 sites in Georgia

   • Centricity Research, Endocrine Consultants, Columbus. 833-602-2368
   • Javara-Fayetteville-67354, Fayetteville. 833-602-2368
   • Balanced Life Health Care Solutions, Lawrenceville. 833-602-2368
   • Rophe Adult and Pediatric Medicine, Union City. 833-602-2368

8. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   3 sites in Georgia

   • Piedmont Hospital, Atlanta. 833-602-2368
   • Gastroenterology Associates of Central Georgia, Macon. 833-602-2368
   • EmVenio Research Center at Prime Healthcare - Riverdale, Riverdale. 833-602-2368

9. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

   Phase 3. Run by Amgen. Registry number NCT07575399.

   A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

   Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

   3 sites in Georgia

   • Nsc Research, Johns Creek
   • Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group, Union City
   • North Georgia Clinical Research, Woodstock

10. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Georgia

    • Gastroenterology Associates of Central Georgia, Macon. 833-602-2368
    • EmVenio Research Center at Prime Healthcare - Riverdale, Riverdale. 833-602-2368

11. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Georgia

    • Care Access - Decatur, Decatur. 678-470-4394
    • North Georgia Clinical Research, Woodstock. 678-494-5735

12. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Georgia

    • Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta. 404-712-4731

13. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Georgia

    • Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta

14. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Georgia

    • Teak Research Consults, Lawrenceville

15. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Georgia

    • Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur. 404-321-6111

16. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Georgia

    • Kailera Clinical Site, Albany

17. Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

    Phase 3. Run by Emory University. Registry number NCT07428746.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 65+, women only, have type 2 diabetes, BMI 27+.

    1 site in Georgia

    • Grady Memorial Hospital, Atlanta. 404-251-5357

18. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Georgia

    • Research Site, Lilburn

19. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    4 sites in Georgia

    • Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville. 770-696-4541
    • Physicians Research Associates, Lawrenceville. 678-252-2375
    • Rophe Adult and Pediatric Medicine/SKYCRNG, Union City. 470-317-3604
    • North Georgia Clinical Research, Woodstock. 678-494-5735

20. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Run by Antag Therapeutics. Registry number NCT07724340.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    3 sites in Georgia

    • CenExel Atlanta, Atlanta. 404-881-5800
    • CenExel Decatur, Decatur. 404-537-1281
    • CenExel Savannah, Savannah. 912-744-0800

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact